{"id":"trx0237","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to tau protein and preventing its aggregation, which is a hallmark of neurodegenerative diseases such as Alzheimer's disease. This mechanism is thought to slow disease progression and potentially halt the progression of cognitive decline.","oneSentence":"TRx0237 is a tau aggregation inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:58.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT03446001","phase":"PHASE3","title":"Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment","status":"COMPLETED","sponsor":"TauRx Therapeutics Ltd","startDate":"2017-12-01","conditions":"Alzheimer Disease","enrollment":598},{"nctId":"NCT03539380","phase":"","title":"TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease","status":"AVAILABLE","sponsor":"TauRx Therapeutics Ltd","startDate":"","conditions":"Alzheimer Disease","enrollment":""},{"nctId":"NCT02245568","phase":"PHASE3","title":"Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)","status":"TERMINATED","sponsor":"TauRx Therapeutics Ltd","startDate":"2014-08","conditions":"Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia","enrollment":913},{"nctId":"NCT04370288","phase":"PHASE1","title":"Clinical Application of Methylene Blue for Treatment of Covid-19 Patients","status":"UNKNOWN","sponsor":"Mashhad University of Medical Sciences","startDate":"2020-04-19","conditions":"Covid-19","enrollment":20},{"nctId":"NCT01626378","phase":"PHASE3","title":"Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)","status":"COMPLETED","sponsor":"TauRx Therapeutics Ltd","startDate":"2013-05","conditions":"Behavioral Variant Frontotemporal Dementia (bvFTD)","enrollment":220},{"nctId":"NCT01689246","phase":"PHASE3","title":"Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"TauRx Therapeutics Ltd","startDate":"2013-01","conditions":"Alzheimer's Disease","enrollment":891},{"nctId":"NCT01689233","phase":"PHASE3","title":"Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease","status":"COMPLETED","sponsor":"TauRx Therapeutics Ltd","startDate":"2012-10","conditions":"Alzheimer's Disease","enrollment":800},{"nctId":"NCT01626391","phase":"PHASE2","title":"Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease","status":"TERMINATED","sponsor":"TauRx Therapeutics Ltd","startDate":"2012-09","conditions":"Alzheimer's Disease","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TRx0237","genericName":"TRx0237","companyName":"TauRx Therapeutics Ltd","companyId":"taurx-therapeutics-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TRx0237 is a tau aggregation inhibitor. Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}